Veeva Systems Inc expects third quarter fiscal year 2027 results to meet or exceed guidance: total revenue $932-935 million, subscription revenue ~$782 million, services revenue $150-153 million, non-GAAP operating income $417-420 million, and non-GAAP fully diluted net income per share $2.33-2.34.
VEEV · Veeva Systems Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY27 earnings call · Aug 26, 2026TL;DR. Q2 revenue and operating earnings grew, results exceeded guidance on all metrics, the full-year outlook improved, and CRM, Falcon, and R&D/Quality advanced. Risks include Falcon’s early readiness and regulatory hurdles, Aspen’s execution and revenue uncertainty, and long EDC implementations.
- + Q2 results exceeded guidance on all metrics and the full-year outlook improved across the board
- + Total revenue rose 18% year over year to $928.0 million and subscription revenue rose 16% to $766.8 million
- + GAAP operating income increased 40% and non-GAAP operating income increased 18% year over year
- + Vault CRM expanded to more than 180 live customers and 12 top-20 commitments
- + Falcon progressed with five early adopters and initial go-lives on track for this year
- + R&D and Quality Cloud adoption broadened, with Safety exceeding 100 customers and Quality adding more than 30
- − Falcon readiness remains a constraint because the product must be prepared before engagement with early adopters
- − Falcon remains too early to declare success and is a new market and motion for Veeva
- − EDC has a long implementation cycle and some wins remain in the ramp-up phase
- − Falcon must clear regulatory hurdles by demonstrating appropriate training and guardrails for human-in-the-loop agents
- − Aspen execution remains uncertain because execution is the hard part in a startup
- − Aspen revenue is not included in current plans
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Diluted net income per share on a non-GAAP basis non-GAAP | $2.35 | Three months ended July 31, 2026 filing | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Diluted net income per share on a GAAP basis $1.66
+$0.83 Stock-based compensation expense
+$0.02 Amortization of purchased intangibles
+$0 Litigation settlement-related charges
-$0.16 Income tax effect on non-GAAP adjustments
= Diluted net income per share on a non-GAAP basis $2.35
|
|||
| Net cash provided by operating activities on a non-GAAP basis non-GAAP | 235.44M | Three months ended July 31, 2026 filing | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities on a GAAP basis 238.71M
-3.27M Excess tax (benefit) deficiency from employee stock plans
= Net cash provided by operating activities on a non-GAAP basis 235.44M
|
|||
| Net income on a non-GAAP basis non-GAAP | 387.41M | Three months ended July 31, 2026 filing | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net income on a GAAP basis 273.43M
+136.8M Stock-based compensation expense
+4.06M Amortization of purchased intangibles
+0K Litigation settlement-related charges
-26.88M Income tax effect on non-GAAP adjustments
= Net income on a non-GAAP basis 387.41M
|
|||
| Operating income on a non-GAAP basis non-GAAP | 415.88M | Three months ended July 31, 2026 filing | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Operating income on a GAAP basis 275.02M
+136.8M Stock-based compensation expense
+4.06M Amortization of purchased intangibles
+0K Litigation settlement-related charges
= Operating income on a non-GAAP basis 415.88M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VEEV
this stock
Veeva Systems Inc
|
$44.88B | +24.2% | +28.1% | 45.4 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$13.60B | +82.5% | +28.2% | 37.1 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$11.60B | +7.7% | +83.4% | — | 13.5% |
|
HNGE
Hinge Health, Inc.
|
$9.31B | +146.6% | +50.6% | 55.9 | 6.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 6, 2026
- This year
- 18
Veeva Systems Inc expects third quarter fiscal year 2027 results to meet or exceed guidance: total revenue $932-935 million, subscription revenue ~$782 million, services revenue $150-153 million, non-GAAP operating income $417-420 million, and non-GAAP fully diluted net income per share $2.33-2.34.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VEEV | -9.1% | -13.5% | +59.0% | -11.4% | +24.2% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -5.2% | -8.0% | +62.5% | -8.1% | +17.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.